Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01471210 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1 study of Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT01471210: Completed Phase 1 study of Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma, sponsored by Bristol-Myers Squibb.
NCT01471210 is a Phase 1 study of Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 124 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (107% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01471210, a Phase 1 study of Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to assess the safety, tolerability, pharmacokinetics and immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or metastatic tumors and relapsed/refractory B-Cell Non-Hodgkin's Lymphoma
Primary Outcome
The incidence of adverse events will be tabulated and reviewed for potential significance and clinical Importance.
Conditions Studied
Interventions
- DRUG Urelumab (BMS-663513)
Study Locations (20)
Other
- Local Institution - Créteil
- Local Institution - Lille
- Local Institution - Paris
- Local Institution - Pessac
- Local Institution - Pierre-Bénite
- Local Institution - Rennes
- Local Institution - Rouen
- Local Institution - Villejuif
California
- Division Of Hematology & Oncology Ctr. For Health Sciences - Los Angeles
- Stanford University Medical Center - Stanford
Pennsylvania
- Penn State Milton S. Hershey Medical Center - Hershey
- Hospital Of The University Of Pennsylvania - Philadelphia
Illinois
- University Of Chicago - Chicago
Indiana
- Indiana University Cancer Center - Indianapolis
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Karmanos Cancer Institute - Detroit
New Jersey
- John Theurer Cancer Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2012-02 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
What the finished NCT01471210 record still lists
NCT01471210 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (107% higher).
The record links to 1 condition, with Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Urelumab (BMS-663513) is the first listed.
NCT01471210 names 20 study sites across 11 states, led by Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01471210 about?
NCT01471210 is a clinical study titled "Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma". The purpose of the study is to assess the safety, tolerability, pharmacokinetics and immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or metastatic tumors and relapsed/refractory B-Cell Non-Hodgkin's Lymphoma
What is the current status of trial NCT01471210?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2012-02. Estimated completion is 2016-04.
What conditions does trial NCT01471210 study?
This clinical trial studies the following conditions: Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT01471210?
The interventions under investigation include: Urelumab (BMS-663513) (DRUG).
Who is sponsoring clinical trial NCT01471210?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01471210 being conducted?
This trial has 20 study locations across California, Illinois, Indiana, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01471210's enrollment target sits among peer trials
124 471st of 2000 higher than 1,526 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia